What do the new data from IMpower010 tell us?

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Sep 20 / Springer Healthcare

What do the new data from IMpower010 tell us?

Oncology Lung Cancer ESMO-2021

Description

Gilberto Lopes outlines the key learnings from the subgroup analyses of the IMpower010 trial that assessed the adjuvant use of atezolizumab after resection and platinum-based chemotherapy in patients with early-stage non-small-cell lung cancer.

Related Content

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.